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Summary
Background: The impact of diabetes mellitus (DM) on muscle mass, muscle strength, and exer-
cise tolerance in patients who had undergone coronary artery bypass grafting (CABG) has not
been fully elucidated.
Methods: We enrolled 329 consecutive patients who received cardiac rehabilitation (CR) after
CABG (DM group, n = 178; non-DM group, n = 151) and measured lean body weight, mid-upper
arm muscle area (MAMA), and handgrip power (HGP) at the beginning of CR. We also per-
formed an isokinetic strength test of the knee extensor (Ext) and ﬂexor (Flex) muscles and a
cardiopulmonary exercise testing at the same time.
Results: No signiﬁcant differences in risk factors, including age, gender, number of diseased
vessels, or ejection fraction were observed between the 2 groups. The levels of Ext muscle
strength, peak oxygen uptake, and anaerobic threshold were signiﬁcantly lower in the DM group
than in the non-DM group (all p < 0.05). Both peak oxygen uptake and MAMA correlated with Ext
and Flex muscle strength as well as HGP (all p < 0.005). The MAMA, HGP, and Ext muscle strength
were lower in patients who received insulin therapy than in those who did not. Interestingly,
fasting glucose levels signiﬁcantly and negatively correlated with Ext muscle strength.
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Conclusions: These data suggest
tolerance than non-DM patients.
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pin DM patients after CABG.
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ndividuals with diabetes mellitus (DM) are at an increased
isk of coronary artery disease (CAD) and DM patients with
AD have poor prognosis [1]. Indeed, DM patients have a
—4 times higher risk of developing CAD and mortality due
o CAD compared with non-DM patients [2]. DM patients ben-
ﬁt from revascularization techniques such as percutaneous
oronary intervention and coronary artery bypass grafting
CABG). However, the beneﬁt is less and the risks and compli-
ations are greater in DM patients than in non-DM patients.
revious studies have reported a high incidence of bypass
raft dysfunction and mortality even in DM patients who
nderwent CABG [3].
It is clear that cardiac rehabilitation (CR) has numerous
eneﬁts such as modulation of risk factors and prevention of
uture cardiovascular events [4]. The improvement in peak
˙O2 after CR signiﬁcantly reduces cardiovascular morbid-
ty and mortality in patients with CAD [5]. However, Savage
t al. demonstrated that in more than 20% of the patients
ho enrolled for CR, there was no improvement in peak V˙O2,
nd that the diagnosis for DM is negatively associated with
he improvement in peak V˙O2 [6]. Vergès et al. reported a
igniﬁcant inverse relationship between fasting blood glu-
ose levels and change in peak V˙O2 in CR participants with
M after acute coronary events [7].
However, the association between muscle mass, muscle
trength, and exercise tolerance in patients with or without
M after CABG has not been fully elucidated. The aim of the
resent study was to investigate the impact of DM on muscle
ass, muscle strength, and exercise tolerance in patients
ho had undergone CABG.
ethods
ubjects
e enrolled 329 consecutive patients who received CR after
ABG at the Juntendo University Hospital from July 2002
o February 2005. The patients were divided into 2 groups:
atients with DM (DM group, n = 178) and patients with-
ut DM (non-DM group, n = 151) according to the guideline
f the Japan Diabetes Society (JDS), including a history
f medical treatment, fasting plasma glucose≥ 126mg/dl
r casual plasma glucose≥ 200mg/dl and hemoglobin (Hb)
1c (JDS)≥ 6.1% [8]. All patients participated in CR after
—8 days of undergoing CABG. All subjects gave written
nformed consent and the ethical committee of the insti-
ution approved this study.
easurementse assessed body composition, muscle strength, and exer-
ise tolerance at the beginning of CR. Anthropometric
arameters were assessed using body mass index and waist
r
w
o
eM. Nishitani et al.
that DM patients had a lower muscle strength and exercise
Moreover, a high glucose level may affect these deteriorations
ology. Published by Elsevier Ltd. All rights reserved.
ircumference. Triceps skin-fold thickness of the dominant
and was measured in millimeters using a caliper, while
he mid-upper arm circumference was measured in cen-
imeters using a tape measure. The mid upper-arm muscle
rea (MAMA) was calculated according to the standard for-
ula [9]. Moreover, we measured the handgrip power (HGP)
f the dominant hand. The percentages of body fat and
ean body weight were measured by a BOD POD® (Life
easurement, Inc., Concord, CA, USA), as we described
reviously [10,11]. In addition, thigh muscle power was mea-
ured using the Cybex770 system (Cybex Division of Lumex,
onkonkoma, NY, USA), as reported earlier [10,11]. The
sokinetic peak torques of the knee extensor (Ext) and ﬂexor
Flex) muscles were measured at 60◦/s; these were adjusted
y body weight according to the following formula: strength
Nm)× 100/body weight (kg). Patients underwent ergome-
er testing (Corival 400, Lobe B.V., Groningen, Netherlands)
sing an expiratory gas analysis machine (Vmax-295, Sen-
orMedics Co., Yorba Linda, CA, USA) to measure peak
xygen consumption (peak V˙O2) and the anaerobic thresh-
ld (AT). After a rest period, a warm-up was performed for
few minutes at 20W, followed by ramp loading (15W/min)
ntil subjective exhaustion, progressive angina, ST-segment
epression (≥2mm), or sustained tachyarrhythmia. The AT
oint was determined by the ‘‘V-slope’’ method.
tatistical analyses
esults are expressed as the mean± standard deviation and
ere analyzed using the StatView software (Version 5.0J
or Windows, SAS Institute, Cary, NC, USA). Comparisons
etween the DM and non-DM groups were performed by a
wo-tailed Student’s t-test. Correlation coefﬁcients (r) were
etermined by linear regression analysis. Statistical signiﬁ-
ance of the correlation coefﬁcients was determined by the
ethod of Fisher and Yates. A p-value of less than 0.05 was
onsidered signiﬁcant.
esults
haracteristics of the study subjects
linical characteristics and anthropometric parameters of
he subjects are presented in Tables 1 and 2. One hundred
nd seventy-eight patients (54%) were diagnosed as hav-
ng DM. No signiﬁcant differences in risk factors, including
ge, gender, number of diseased vessels, ejection fraction,
nd physiological variables were observed between the DM
nd non-DM groups. Three hundred and twenty-ﬁve patients
99%) received complete revascularization using the off-
ump operation. Eight patients (4%) who had undergone
e-CABG were in the DM group. No signiﬁcant differences
ere observed between the 2 groups for the concomitant use
f drugs such antiplatelet agents, calcium-channel block-
rs, -blockers, angiotensin-converting enzyme inhibitors,
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Table 1 Clinical characteristics of the study subjects.
DM Non-DM p value
N 178 151
Age (year) 64.7 ± 9.2 65.8 ± 9.2 NS
Male (%) 143 (80) 120 (79) NS
Hypertension (%) 116 (66) 111 (74) NS
Dyslipidemia (%) 109 (62) 108 (72) NS
Current smoker (%) 91 (54) 72 (49) NS
Familial history (%) 40 (24) 33 (23) NS
Fasting blood glucose (mg/dl) 159 ± 63 108 ± 24 <0.01
HbA1c (%) 7.1 ± 1.3 5.1 ± 0.4 <0.01
LDL-C (mg/dl) 115 ± 34 110 ± 41 NS
HDL-C (mg/dl) 47 ± 13 48 ± 13 NS
Triglyceride (mg/dl) 140 ± 77 143 ± 76 NS
Creatinine (mg/dl) 1.3 ± 1.7 1.2 ± 1.9 NS
C-reactive protein (mg/dl) 0.5± 1.5 0.3 ± 0.3 NS
History of MI (%) 38 (28) 31 (25) NS
History of PCI (%) 4 (2) 0 (0) NS
History of previous CABG (%) 8 (4) 0 (0) NS
Diseased vessels
LMT (%) 36 (20) 21 (14) NS
3VD (%) 103 (58) 89 (59) NS
1—2VD (%) 39 (22) 41 (27) NS
Ejection fraction (%) 57.3 ± 15.2 59.1 ± 16.3 NS
Off-pump CABG (%) 174 (98) 151 (100) NS
Data are presented as the mean value± SD. DM, diabetes mellitus; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol;
ion;
p
v
P
o
p
m
H
o
DHDL-C, high-density lipoprotein cholesterol; MI, myocardial infarct
bypass grafting; LMT, left main trunk; VD, vessel disease.
angiotensin II receptor blockers, and statins. In the DM
group, 110 patients (61%) and 55 (31%) patients were treated
with oral anti-diabetic agents and insulin, respectively.
Exercise tolerance and muscle strength
The exercise tolerance and muscle strength of the 2
groups are presented in Table 3. The levels of peak V˙O2
(12.5± 3.7ml kg−1 min−1 vs. 13.7± 4.0ml kg−1 min−1;
p = 0.01) and AT (8.3± 1.6ml kg−1 min−1 vs.
8.8± 2.1ml kg−1 min−1, p = 0.02) were signiﬁcantly lower in
the DM group than in the non-DM group. Ext muscle strength
was signiﬁcantly lower in the DM group than in the non-DM
group (131± 40Nmkg−1 × 100 vs. 146± 45Nmkg−1 × 100,
T
p
i
Table 2 Comparison of anthropometric parameters between the
DM
Body mass index (kg/m2) 23.3 ±
Lean body weight (kg) 49.2 ±
Waist circumference (cm) 84.8 ±
Thigh circumference (cm) 47.0 ±
Arm forced circumference (cm) 28.3 ±
Triceps skinford thickness (mm) 10.9 ±
Mid-upper arm muscle circumference (cm) 24.9 ±
MAMA (cm2) 50.0 ±
Data are presented as the mean± SD. DM, diabetes mellitus; MAMA, mPCI, percutaneous coronary intervention; CABG, coronary arterial
< 0.01). No signiﬁcant differences in HGP (27.7± 9.0 kg
s. 29.5± 9.0 kg, NS) were observed between the 2 groups.
eak V˙O2 values were correlated with Ext muscle strength
f thigh (r = 0.49, p < 0.005) (Fig. 1A) and HGP (r = 0.44,
< 0.005) (Fig. 1B); MAMA values were correlated with Ext
uscle strength of thigh (r = 0.42, p < 0.005) (Fig. 2A) and
GP (r = 0.64, p < 0.005) (Fig. 2B). The same trends were
bserved in the DM and non-DM patients (Figs. 1C—F, 2C—F).
iabetes mellitus and MAMAo assess the effects of insulin treatment, we divided DM
atients into the following 2 groups: DM patients undergoing
nsulin therapy (insulin-treated DM group) and DM patients
DM and non-DM groups.
Non-DM p value
2.7 23.2 ± 2.7 NS
8.6 48.0 ± 4.1 NS
8.0 84.0 ± 8.0 NS
6.7 48.1 ± 4.1 NS
2.7 28.7 ± 2.5 NS
6.0 10.7 ± 4.0 NS
2.6 25.4 ± 2.5 NS
10.0 52.0 ± 10.0 NS
id-upper arm muscle area.
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Table 3 Comparison of exercise tolerance and muscle strength between the DM and non-DM groups.
DM Non-DM p value
Baseline
SBP (mmHg) 134 ± 23 128 ± 19 <0.01
HR (min−1) 87 ± 13 90 ± 13 0.04
PRP (mmHgmin−1) 11673 ± 2333 11634 ± 2280 NS
Anaerobic threshold
Anaerobic threshold (ml kg−1 min−1) 8.3 ± 1.6 8.8 ± 2.1 0.02
Workload (W) 32 ± 12 34 ± 16 NS
HR (min−1) 101 ± 13 105 ± 13 0.01
Peak exercise
Peak VO2 (ml kg−1 min−1) 12.5 ± 3.7 13.7 ± 4.0 0.01
Workload (W) 73 ± 22 71 ± 27 NS
RER 1.06 ± 0.14 1.07 ± 0.14 NS
SBP (mmHg) 180 ± 31 181 ± 30 NS
HR (min−1) 117 ± 17 121 ± 17 0.02
PRP (mmHgmin−1) 21177 ± 5097 22088 ± 5427 NS
Peak HR—resting HR (min−1) 30 ± 13 32 ± 15 NS
VO2/WR (mlmin−1 W−1) 8.4 ± 2.6 8.6 ± 2.2 NS
Muscle strength
Knee extension (Nmkg−1 × 100) 131 ± 40 146 ± 45 <0.01
Knee ﬂexion (Nmkg−1 × 100) 73 ± 23 79 ± 28 NS
Hand grip power (kg) 27.7 ± 9.0 29.5 ± 9.0 NS
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DData are presented as the mean value± SD. DM, diabetes melli
product; RER, respiratory exchange ratio; WR, work rate.
ithout insulin therapy (non-insulin-treated DM group). No
igniﬁcant differences in risk factors, number of diseased
essels, prevalence of re-CABG, and ejection fraction were
bserved between the non-insulin-treated DM group and the
nsulin-treated DM group. The insulin-treated DM group had
signiﬁcantly longer duration of DM history than the non-
nsulin-treated DM group (17.7± 9 years vs. 11.7± 10 years,
< 0.01). The prevalence of microvascular complications,
ncluding retinopathy, nephropathy, and neuropathy, tended
o be higher in the insulin-treated DM group than in the non-
nsulin-treated DM group (86% vs. 67%, p = 0.09). MAMA levels
ere signiﬁcantly lower in the insulin-treated DM group
han in the non-insulin-treated DM group (45.9± 9.8 cm2 vs.
1.9± 9.7 cm2, p < 0.01). The insulin-treated DM group had
low thigh muscle strength (121.5± 29Nmkg−1 × 100 vs.
35.4± 42Nmkg−1 × 100, p = 0.06) and HGP (25.6± 8.0 kg
s. 28.9± 8.0 kg, p = 0.05). In addition, a signiﬁcant inverse
elationship was observed between fasting blood glucose
nd Ext muscle strength of thigh in the DM group (r =−0.26,
< 0.005) (Fig. 3). A weak but signiﬁcant inverse relationship
as also observed between HbA1c and Ext muscle strength
f thigh (r =−0.17, p < 0.05).
iscussion
n the present study, we demonstrated that: (1) DM patients
ad a signiﬁcantly lower exercise tolerance and muscle
trength compared with non-DM patients; (2) exercise toler-
nce and muscle mass correlated with muscle strength; and
3) fasting glucose levels signiﬁcantly and negatively cor-
elated with muscle strength in patients who received CR
fter CABG. These data suggest that a high glucose level
e
s
r
iSBP, systolic blood pressure; HR, heart rate; PRP, pressure rate
ay affect these deteriorations in DM patients after CABG.
relationship between muscle strength and peak V˙O2 has
lready been reported [12,13]. However, to the best of our
nowledge, this is the ﬁrst report demonstrating the impact
f DM on muscle mass, muscle strength, and exercise toler-
nce in patients at the beginning of CR after CABG.
The reason why DM patients have low levels of
xercise tolerance and muscle strength should be dis-
ussed. Tesfamariam et al. showed that the dysfunction
f endothelium-dependent relaxation associated with expo-
ure to elevated glucose levels is due to the increased
roduction of vasoconstrictor prostanoids by the endothe-
ium as a consequence of protein kinase C activation [14].
revious studies have demonstrated that metabolisms of
oth glucose and fatty acids by skeletal muscle as well as
he bioenergetic capacity of skeletal muscle mitochondria
re impaired in DM patients [15]. These proposed mecha-
isms may explain the data in the present study because a
igniﬁcant inverse relationship was observed between fast-
ng blood glucose levels and thigh muscle strength in the
M group (Fig. 3). Recently, Womack et al. showed that
M patients with microvascular complications have impaired
apillary recruitment to contractile exercise [16]. In the
resent study, the prevalence of microvascular complica-
ions tended to be higher in the insulin-treated DM group
han in the non-insulin-treated DM group. This may also
e one of the mechanisms by which thigh muscle strength
nd HGP were signiﬁcantly lower in the insulin-treated
M group than in the non-insulin-treated DM group. Low
xercise tolerance in DM patients may be caused by sen-
orineural and autonomic dysfunction. An impaired heart
ate response to exercise has been regarded as chronotropic
ncompetence and is seen in DM patients with impaired
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Figure 1 Correlations between exercise tolerance and muscle strength. Peak V˙O2 correlated with extensor muscle strength of
thigh (r = 0.49, p < 0.005) (A), and HGP (r = 0.44, p < 0.005) in all patients (B) (n = 259). Peak V˙O2 correlated with extensor muscle
strength of thigh (r = 0.48, p < 0.005) (C), and HGP (r = 0.43, p < 0.005) in the DM group (D) (n = 128). Peak V˙O2 correlated with
GP (
T
n
Textensor muscle strength of thigh (r = 0.46, p < 0.005) (E), and H
grip power; DM, diabetes mellitus.
exercise capacity. A previous study showed that low exer-
cise capacity may be an impaired chronotropic response
to exercise in DM patients with acute myocardial infarc-
tion [17]. In the present study, the heart rate values at
peak V˙O2 and AT were signiﬁcant lower in the DM group
than in the non-DM group; however, the increased changes
in heart rate were identical for the two groups (Table 3).
c
t
B
br = 0.45, p < 0.005) in the non-DM group (F) (n = 131). HGP, hand
herefore, sensorineural and autonomic dysfunction may
ot have affected exercise intolerance in the DM group.
he changes in sympathetic nervous activity (e.g. plasma
atecholamine levels and R—R interval variability on an elec-
rocardiogram) would be assessed in the subsequent step.
esides, a delta-V˙O2/delta-WR (V˙O2/WR) is determined
y the rate of increase in cardiac output and the rate of
178 M. Nishitani et al.
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Figure 2 Correlations between muscle strength and muscle mass. MAMA correlated with extensor muscle strength of thigh (r = 0.42,
p < 0.005) (A), and HGP (r = 0.64, p < 0.005) (B) in all patients (n = 201). MAMA correlated with extensor muscle strength of thigh
(r = 0.50, p < 0.005) (C), and HGP (r = 0.66, p < 0.005) (D) in DM patients (n = 108). MAMA correlated with extensor muscle strength of
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thigh (r = 0.35, p < 0.005) (E), and HGP (r = 0.63, p < 0.005) (F) in
and grip power; DM, diabetes mellitus.
ifference in arterial mixed venous oxygen during incre-
ental exercise [18]. Comparing with the non-DM group,
V˙O2/WR values were low but not signiﬁcant in the DM
roup (Table 3).
The present study demonstrated that MAMA correlated
ith thigh muscle strength and HGP and MAMA levels were
igniﬁcantly lower in the insulin-treated DM group than
he non-insulin-treated DM group. Chronic hyperglycemia
eads to the production of amadori products through nonen-
ymatic glycation reactions between glucose and reactive
mino groups of serum proteins [19]. These products
h
m
s
t-DM patients (n = 93). MAMA, mid-upper arm muscle area; HGP,
ndergo further irreversible reactions to form advanced
lycation end products that promote insulin resistance as
ell as trigger inﬂammation and secretion of cytokines and
rowth factors, which leads to ampliﬁcation or progression
f various diseases including diabetic vascular complications
metabolic memory) [20]. In the present study, the insulin-
reated DM group had a signiﬁcantly longer duration of DM
istory than the non-insulin-treated DM group. The loss of
uscle mass may be caused by chronic hyperglycemia, the
o-called negative legacy effect, particularly in the insulin-
reated DM group. A recent study demonstrated that a low
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(r =−0.26, p < 0.005) (n = 120).
level of arm muscle area was an independent risk factor
for the 2-year mortality in a cohort of community dwelling
Japanese elderly [21]. We would like to further clarify
whether the levels of arm muscle area before and after
CR can predict morbidity and mortality in DM patients after
CABG.
CR is class I recommendation in most contemporary car-
diovascular clinical practice guidelines. Exercise tolerance
has proven to be the strongest predictor of the risk of death
among subjects with and without known cardiovascular dis-
ease [22]. Vergès et al. reported that the beneﬁt of CR
on exercise capacity is signiﬁcantly lower in DM patients
than non-DM patients and the response to CR was inﬂuenced
by blood glucose levels [7]. A previous study demonstrated
that exercise increases the activity of AMP-activated pro-
tein kinase in muscle, which in turn, promotes translocation
of the glucose transporter-4 from the cytosol to the plasma
membrane, increases insulin-independent glucose uptake by
muscle, and improves muscle insulin resistance by a reduc-
tion of intramyocellular lipids [23]. Therefore, it is necessary
to investigate the effects of CR on muscle mass, muscle
strength, exercise capacity, and long-term outcome.
The present study has some limitations. First, this was
a single-center study with a small sample size. Studies
with larger sample sizes can conﬁrm these results. Sec-
ondly, we performed a cardiopulmonary exercise test at the
beginning of phase I CR (6—8 days after CABG). Therefore
exercise tolerance and muscle strength might be attenuated
by confounding factors. However, no signiﬁcant differences
in the clinical characteristics were observed between the DM
group and the non-DM group. Thirdly, we enrolled patients
who received CR after CABG. Therefore, the results of the
present study may not be representative of all DM patients
with CAD. Finally, this was a cross-sectional study. As dis-
[G 179
ussed above, the clinical importance of muscle parameters
nd exercise tolerance prospectively as well as the effects
f CR on muscle mass, muscle strength, exercise capacity,
nd future cardiovascular events in DM patients after CABG
ust be investigated.
onclusions
M patients had a lower muscle strength and exercise tol-
rance than non-DM patients at the beginning of CR after
ABG. Moreover, a high glucose level may affect these dete-
iorations in DM patients after CABG. Further studies are
equired to assess whether CR would ameliorate these dete-
iorations and improve the clinical prognosis in DM patients
fter CABG.
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